The new products will allow next generation sequencer users to perform pinpointed sequencing of portions of the human genome. This would, in effect, mean a faster and cheaper method of getting the desired genetic information from the sample of an individual.

Currently, DNA sequencers rapidly sequence the entire genome, giving out large amounts of data. In a recent interaction with Business Line he said, Agilent has also been selected for a landmark Copy Number Variation (CNV) project covering 19,000 patients. The study’s goal is to gain a better understanding of 12 complex diseases, including breast cancer. The project was awarded by the Wellcome Trust Case Control Consortium (WTCCC). It will use a highly-automated protocol which includes the use of the Velocity 11 Bravo robot for sample preparation.